Intra-Cellular Therapies (NSDQ:ITCI) has announced that Caplyta (lumateperone) has become the only FDA-approved monotherapy for depressive episodes linked to bipolar I or II disorder (bipolar depression). The approval also covers its use as adjunctive therapy with lithium or valproate. Lumateperone was initially FDA approved in 2019 as an atypical antipsychotic for treating schizophrenia in adults.…